Tocagen Inc. Falls Over 80% After Late-stage Trial Fails to Meet Endpoint

Shares of Tocagen Inc. were plummeting on Thursday, falling over 80% to a new record low as the company announced a late-stage trial of its brain cancer treatment did not meet the primary endpoint.

The gene company said the study failed to meet its primary endpoint of survival compared with standard of care treatment. Tocagen also said that secondary endpoints of the phase 3 trial evaluating Toca 511 and Toca FC in patients with recurrent high grade glioma undergoing resection showed no meaningful difference between the arms of the trial.

According to the company’s press release, Toca 5 Phase 3, randomized, multi-center clinical trial evaluating Toca 511 & Toca FC in patients with recurrent high grade glioma (HGG) undergoing resection missed the primary endpoint of overall survival compared to standard of care treatment (11.1 months median compared to 12.2 months, HR=1.06, p=0.6154). In addition, all secondary endpoints showed no meaningful difference between the arms of the trial. The safety, tolerability and adverse event profile of Toca 511 & Toca FC was as expected for this patient population.

Toca 5 Phase 3, randomized, multi-center clinical trial evaluating Toca 511 & Toca FC in patients with recurrent high grade glioma (HGG) undergoing resection missed the primary endpoint of overall survival compared to standard of care treatment (11.1 months median compared to 12.2 months, HR=1.06, p=0.6154).

In addition, all secondary endpoints showed no meaningful difference between the arms of the trial. The safety, tolerability and adverse event profile of Toca 511 & Toca FC was as expected for this patient population.

Disclaimer: We have no position in Tocagen Inc. (Nasdaq: TOCA) and have not been compensated for this article.